<?xml version="1.0" encoding="UTF-8"?>
<p id="Par28">Data used in the preparation of this article were obtained from the PPMI database (
 <ext-link ext-link-type="uri" xlink:href="http://www.ppmi-info.org/data" xmlns:xlink="http://www.w3.org/1999/xlink">www.ppmi-info.org/data</ext-link>). For up-to-date information on the study, visit 
 <ext-link ext-link-type="uri" xlink:href="http://www.ppmi-info.org" xmlns:xlink="http://www.w3.org/1999/xlink">www.ppmi-info.org</ext-link>. PPMI—a public–private partnership—is funded by the Michael J. Fox Foundation for Parkinson’s Research and funding partners, including Abbvie, Avid Radiopharmaceuticals, Biogen, Bristol-Myers Squibb, Covance, GE Healthcare, Genentech, GlaxoSmithKline, Lilly, Lundbeck, Merck, Meso Scale Discovery, Pfizer, Piramal, Roche, Servier, and UCB.
</p>
